Stock Ratings / Health Care / XBIO / options

APUS (43) ADXN (57) CANF (31) PULM (36) ⌘ Pro Terminal →

Xenetic Biosciences Inc. (XBIO) Options Positioning, Max Pain & Unusual Sweeps

$2.12 +0.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.12

Xenetic Biosciences Inc. (XBIO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $5.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.12 (-0.02%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-4.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XBIO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY XBIO SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 43.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$2.13-6.6% Next Q

Q2 (-2Q)

Grade C-$1.99-13.6% Next Q

Q3 (-1Q)

Grade C-$1.72+23.3% Next Q

Current

Grade D$2.12-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XBIO currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.85) and Max Pain ($2.23) forces dealer call-delta covering toward $5.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (XBIO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for XBIO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XBIO)

✓Walkthrough of XBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.03%📐 HORIZONTAL RANGE

2026-10-30O $2.14H $2.15L $1.95C $2.12VOL 32.6K

RES: $5.74SUP: $1.54SMA50: $2.85SMA200: $2.84

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XBIO Butterfly Map → + Track XBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XBIO)

Health Care Rank #430 of 1016 ⚔️ APUS vs XBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XBIO vs. APUS, ADXN, CANF, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xenetic Biosciences Inc. (XBIO) ranks #430 by composite RQD confidence (47/100, grade D) and #948 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, XBIO leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with XBIO at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XBIO ACTIVE Xenetic Biosciences Inc.	D	47/100	—	—	-30.3%	+0.95%	$5.0M	Benchmark Subject
APUS Apimeds Pharmaceuticals US Inc.	D-	43/100	—	—	-6.2%	+4.56%	$5.0M	/apus-vs-xbio →
ADXN Addex Therapeutics Ltd	D+	57/100	—	—	—	-1.01%	$5.0M	/adxn-vs-xbio →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	31/100	—	—	-35.0%	+0.61%	$5.0M	/canf-vs-xbio →
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-xbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001534525

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xenetic Biosciences Inc. (XBIO) reported GAAP revenue of $3.0M (+19.0% vs. FY2024 revenue of $2.5M , and +17.2% cumulative change since FY2023) , GAAP net income of -$2.7M, operating cash flow of -$2.3M, and free cash flow of -$2.3M (+18.8% YoY). On the balance sheet, XBIO closed FY2025 with $8.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.0M	-$2.7M	-$2.3M	-$2.3M	$8.4M	—
FY2024 (FY)	2024-12-31	$2.5M	-$4.0M	-$2.8M	-$2.8M	$6.9M	—
FY2023 (FY)	2023-12-31	$2.5M	-$4.1M	-$4.1M	-$4.1M	—	—

3. XBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Xenetic Biosciences Inc. (NASDAQ: XBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $2.12 (+0.95% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XBIO ranks #430 in composite RQD confidence.

How does XBIO compare to APUS and ADXN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.3%. By comparison, APUS (Apimeds Pharmaceuticals US Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -6.2%, cap $5.0M) and ADXN (Addex Therapeutics Ltd) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $5.0M). Among the 5-stock peer group, XBIO leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XBIO?

Per XBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534525), Xenetic Biosciences Inc. generated $3.0M in revenue (+19.0% YoY), -$2.7M in net income, and -$2.3M in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

XBIO last traded at $2.12 (+0.95% on volume of 34,454 shares), positioning the stock -25.61% below its 50-day simple moving average ($2.85) and -25.35% below its 200-day simple moving average ($2.84). Across its 52-week range of $1.58 to $4.94, XBIO sits at the 16.1% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.85 to $2.39).

XBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is XBIO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for XBIO.

Direct Sub-Reports: XBIO RQD Cockpit XBIO 12M Forecast XBIO Earnings & Move XBIO Dividends & DRIP XBIO Insiders & 13F XBIO Whale Options XBIO Profit Sankey XBIO News & Why